Literature DB >> 28449955

Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

Brantley P Jarvis1, August F Holtyn1, Meredith S Berry1, Shrinidhi Subramaniam1, Annie Umbricht1, Michael Fingerhood1, George E Bigelow1, Kenneth Silverman2.   

Abstract

BACKGROUND AND AIM: Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4weeks; however, starting treatment can be challenging because it requires 7 to 10days of abstinence from all opioids. In the present study we identified patient and treatment characteristics that were associated with successful induction onto XR-NTX.
METHODS: 144 unemployed heroin-dependent adults who had recently undergone opioid detoxification completed self-report measures and behavioral tasks before starting an outpatient XR-NTX induction procedure. Employment-based reinforcement was used to promote opioid abstinence and adherence to oral naltrexone during the induction. Participants were invited to attend a therapeutic workplace where they earned wages for completing jobs skills training. Participants who had used opioids recently were initially invited to attend the workplace for a 7-day washout period. Then those participants were required to provide opioid-negative urine samples and then take scheduled doses of oral naltrexone to work and earn wages. Participants who had not recently used opioids could begin oral naltrexone immediately. After stabilization on oral naltrexone, participants were eligible to receive XR-NTX and were randomized into one of four treatment groups, two of which were offered XR-NTX. Binary and multiple logistic regressions were used to identify characteristics at intake that were associated with successfully completing the XR-NTX induction.
RESULTS: 58.3% of participants completed the XR-NTX induction. Those who could begin oral naltrexone immediately were more likely to complete the induction than those who could not (79.5% vs. 25.0%). Of 15 characteristics, 2 were independently associated with XR-NTX induction success: legal status and recent opioid detoxification type. Participants who were not on parole or probation (vs. on parole or probation) were more likely to complete the induction (OR [95% CI]=2.5 [1.1-5.7], p=0.034), as were those who had come from a longer-term detoxification program (≥21days) (vs. a shorter-term [<21days]) (OR [95% CI]=7.0 [3.0-16.6], p<0.001).
CONCLUSIONS: Our analyses suggest that individuals recently leaving longer-term opioid detoxification programs are more likely to complete XR-NTX induction. Individuals on parole or probation are less likely to complete XR-NTX induction and may need additional supports or modifications to induction procedures to be successful.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extended-release naltrexone; Heroin; Induction; Opioids

Mesh:

Substances:

Year:  2017        PMID: 28449955      PMCID: PMC5650550          DOI: 10.1016/j.jsat.2017.04.012

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  31 in total

1.  Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART).

Authors:  C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown
Journal:  J Exp Psychol Appl       Date:  2002-06

2.  Baseline characteristics of patients predicting suitability for rapid naltrexone induction.

Authors:  Shanthi Mogali; Nabil A Khan; Esther S Drill; Martina Pavlicova; Maria A Sullivan; Edward Nunes; Adam Bisaga
Journal:  Am J Addict       Date:  2015-04

3.  Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.

Authors:  Lisa A Marsch; Mary Ann Chutuape Stephens; Timothy Mudric; Eric C Strain; George E Bigelow; Rolley E Johnson
Journal:  Exp Clin Psychopharmacol       Date:  2005-11       Impact factor: 3.157

4.  A demonstration project implementing extended-release naltrexone in Los Angeles County.

Authors:  Sarah J Cousins; Loretta Denering; Desirée Crèvecoeur-MacPhail; John Viernes; Wayne Sugita; James Barger; Tina Kim; Stefanie Weimann; Richard A Rawson
Journal:  Subst Abus       Date:  2015-07-09       Impact factor: 3.716

5.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

6.  Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN.

Authors:  W M Compton; L B Cottler; K B Dorsey; E L Spitznagel; D E Mager
Journal:  Drug Alcohol Depend       Date:  1996-07       Impact factor: 4.492

7.  Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.

Authors:  Kelly E Dunn; Anthony Defulio; Jeffrey J Everly; Wendy D Donlin; Will M Aklin; Paul A Nuzzo; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Exp Clin Psychopharmacol       Date:  2012-12-03       Impact factor: 3.157

8.  Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.

Authors:  Lisa A Uebelacker; Genie Bailey; Debra Herman; Bradley Anderson; Michael Stein
Journal:  J Subst Abuse Treat       Date:  2016-03-09

9.  Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors.

Authors:  Ingrid A Binswanger; Carolyn Nowels; Karen F Corsi; Jason Glanz; Jeremy Long; Robert E Booth; John F Steiner
Journal:  Addict Sci Clin Pract       Date:  2012-03-15

10.  Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013.

Authors:  Christopher M Jones; Joseph Logan; R Matthew Gladden; Michele K Bohm
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-10       Impact factor: 17.586

View more
  7 in total

1.  The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.

Authors:  Brantley P Jarvis; August F Holtyn; Anthony DeFulio; Mikhail N Koffarnus; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2019-02-14       Impact factor: 4.492

2.  Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.

Authors:  Ramin Mojtabai; Christine Mauro; Melanie M Wall; Colleen L Barry; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2019-01       Impact factor: 6.301

3.  Changes in cardiac vagal tone as measured by heart rate variability during naloxone-induced opioid withdrawal.

Authors:  Charles J Levin; Jonathan M Wai; Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2019-09-03       Impact factor: 4.492

4.  Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.

Authors:  Matisyahu Shulman; Mei-Chen Hu; Maria A Sullivan; Sarah C Akerman; James Fratantonio; Vincent Barbieri; Edward V Nunes; Adam Bisaga
Journal:  Drug Alcohol Depend       Date:  2022-02-02       Impact factor: 4.492

Review 5.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

6.  Development of a Clinically Viable Heroin Vaccine.

Authors:  Paul T Bremer; Joel E Schlosburg; Matthew L Banks; Floyd F Steele; Bin Zhou; Justin L Poklis; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-06-20       Impact factor: 15.419

Review 7.  Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Authors:  Virginia Perez-Macia; Mireia Martinez-Cortes; Jesus Mesones; Manuel Segura-Trepichio; Lorena Garcia-Fernandez
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.